Simulations Plus, Inc. (NASDAQ:SLP) Plans $0.06 Quarterly Dividend

Simulations Plus, Inc. (NASDAQ:SLP) announced a quarterly dividend on Tuesday, July 2nd, NASDAQ reports. Investors of record on Monday, July 29th will be paid a dividend of 0.06 per share by the technology company on Monday, August 5th. This represents a $0.24 annualized dividend and a dividend yield of 0.60%. The ex-dividend date is Monday, July 29th.

Simulations Plus has a dividend payout ratio of 30.8% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Simulations Plus to earn $0.72 per share next year, which means the company should continue to be able to cover its $0.24 annual dividend with an expected future payout ratio of 33.3%.

Simulations Plus Stock Down 14.9 %

NASDAQ SLP traded down $6.97 during trading hours on Wednesday, hitting $39.89. The company had a trading volume of 340,695 shares, compared to its average volume of 104,824. The firm has a market cap of $797.40 million, a P/E ratio of 75.26 and a beta of 0.72. Simulations Plus has a fifty-two week low of $32.69 and a fifty-two week high of $52.69. The business has a fifty day simple moving average of $47.81 and a 200-day simple moving average of $44.18.

Simulations Plus (NASDAQ:SLP) last released its quarterly earnings results on Tuesday, July 2nd. The technology company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.15 by $0.04. The business had revenue of $18.54 million during the quarter, compared to analyst estimates of $17.92 million. Simulations Plus had a net margin of 16.22% and a return on equity of 7.95%. The company’s quarterly revenue was up 14.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.20 earnings per share. Equities analysts forecast that Simulations Plus will post 0.55 EPS for the current fiscal year.

Insider Buying and Selling at Simulations Plus

In related news, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $45.95, for a total value of $919,000.00. Following the completion of the sale, the director now directly owns 3,580,857 shares of the company’s stock, valued at approximately $164,540,379.15. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $45.95, for a total value of $919,000.00. Following the completion of the sale, the director now owns 3,580,857 shares in the company, valued at approximately $164,540,379.15. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Daniel L. Weiner sold 3,250 shares of the business’s stock in a transaction on Tuesday, May 7th. The shares were sold at an average price of $48.31, for a total transaction of $157,007.50. Following the transaction, the director now owns 8,759 shares in the company, valued at $423,147.29. The disclosure for this sale can be found here. Insiders have sold a total of 44,500 shares of company stock valued at $2,072,198 in the last three months. 20.90% of the stock is currently owned by company insiders.

Analyst Ratings Changes

SLP has been the topic of several recent analyst reports. Craig Hallum reaffirmed a “buy” rating and set a $56.00 target price on shares of Simulations Plus in a research note on Wednesday. Oppenheimer lifted their price objective on shares of Simulations Plus from $55.00 to $65.00 and gave the company an “outperform” rating in a research note on Thursday, June 13th. Finally, William Blair initiated coverage on shares of Simulations Plus in a research report on Friday, June 28th. They issued an “outperform” rating for the company.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.